How does bupropion work as a smoking cessation aid?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical and clinical mechanism-based reasoning without systematic review methodology.
PubMed 16109583 · doi:10.1080/13556210500222670
What was done
This narrative review evaluated the pharmacological mechanisms of bupropion as a smoking cessation aid by synthesizing clinical observations with evidence from preclinical in vivo and in vitro experiments.
What was found
The abstract reports no numerical findings or statistical estimates. It notes that bupropion is a weak dopamine and noradrenaline reuptake inhibitor, antagonizes nicotinic acetylcholine receptors, and is extensively metabolized into major metabolites that reach higher levels than the parent drug. The review concluded that bupropion primarily alleviates withdrawal symptoms by mimicking nicotinic effects on catecholamines, and that nicotinic receptor antagonism may help prevent relapse by reducing nicotine reinforcement rather than acutely reducing smoking.
Why it matters
This review distinguishes between bupropion's roles in withdrawal alleviation versus relapse prevention, while highlighting that active metabolites—often overlooked in research—may drive its clinical efficacy in smoking cessation.
Limits
This is a narrative review lacking a systematic search strategy, explicit study selection criteria, or quantitative synthesis. No participant numbers or study counts are reported in the abstract. Much of the mechanistic framework relies on preclinical in vitro and animal models rather than direct clinical pharmacodynamic data.
Cited by
- supports Wellbutrin (bupropion) increases dopamine and norepinephrine broadly across the brain rather than targeting specific circuits.